X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PRGN-2012 is an innovative therapeutic vaccine with optimized antigen design that uses gorilla adenovector technology. It is under phase 1/2 clinical development for the treatment of recurrent respiratory papillomatosis.
Lead Product(s): PRGN-2012
Therapeutic Area: Infections and Infectious Diseases Product Name: PRGN-2012
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
PRGN-2012 is an innovative therapeutic vaccine with optimized antigen design that uses Precigen’s gorilla adenovector technology (proprietary AdenoVerse platform), which is investigated for the treatment of recurrent respiratory papillomatosis.
Lead Product(s): PRGN-2012
Therapeutic Area: Infections and Infectious Diseases Product Name: PRGN-2012
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
PRGN-2012 is an innovative therapeutic vaccine with optimized antigen design that uses Precigen’s gorilla adenovector technology (proprietary AdenoVerse platform), which is investigated for the treatment of recurrent respiratory papillomatosis.
Lead Product(s): PRGN-2012
Therapeutic Area: Infections and Infectious Diseases Product Name: PRGN-2012
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
PRGN-2009 leverages Precigen’s UltraVector® and AdenoVerse™ platforms and is an off-the-shelf adenoVerse immunotherapy in combination with pembrolizumab being developed to treat patients with recurrent or metastatic cervical cancer.
Lead Product(s): PRGN-2009,Pembrolizumab
Therapeutic Area: Oncology Product Name: PRGN-2009
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
Under the agreement, Precigen regains exclusive rights to IL-12 gene therapy, including application through the AdenoVerse™ platform. Precigen will utilize the UltraCAR-T platform for unencumbered development and commercialization of two proven CAR-T targets, CD19 and BCMA.
Lead Product(s): Autologous CAR-T Cell-based Therapy,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: PRGN-3007
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: Alaunos Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 03, 2023
Details:
PRGN-3007 is the next generation of UltraCAR-T incorporating PD-1 inhibition, it simultaneously express a chimeric antigen receptor (CAR) targeting ROR1, mbIL15, a kill switch, and a novel mechanism for the intrinsic blockade of PD-1 gene. expression.
Lead Product(s): PRGN-3007,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: PRGN-3007
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
PRGN-2012 is an innovative therapeutic vaccine with optimized antigen design that uses Precigen’s gorilla adenovector technology (proprietary AdenoVerse platform), to elicit immune responses directed against cells infected with human papillomavirus type 6 or HPV type 11.
Lead Product(s): PRGN-2012
Therapeutic Area: Infections and Infectious Diseases Product Name: PRGN-2012
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
PRGN-3006 UltraCAR-T is a multigenic autologous chimeric antigen receptor (CAR)-T simultaneously expressing a CAR specifically targeting CD33; membrane bound IL-15 (mbIL15) for enhanced in vivo expansion and persistence.
Lead Product(s): PRGN-3006
Therapeutic Area: Oncology Product Name: PRGN-3006
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
PRGN-3006 UltraCAR-T has demonstrated a favorable safety profile to date with no dose-limiting toxicities or neurotoxicity, and has demonstrated dose-dependent in vivo expansion and durable persistence.
Lead Product(s): PRGN-3006
Therapeutic Area: Oncology Product Name: PRGN-3006
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
PRGN-2009 an OTS investigational immunotherapy showed positive interim results and significant unmet patient need will now undergo Phase 2 trial in combination with an anti-PD-1 checkpoint inhibitor in advanced human papillomavirus-associated cancer.
Lead Product(s): PRGN-2009
Therapeutic Area: Oncology Product Name: PRGN-2009
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
